Table 4 Other key input parameters
Parameters | Value | Range | Source |
|---|---|---|---|
Discontinuation rate due to AEs in initial treatment | |||
 Vd | 15.58% | 12.46%—18.69% | |
 DVd | 17.92% | 14.34%—21.50% | |
 SVd | 20.44% | 16.35%—24.53% | [26] |
 PVd | 9.52% | 7.61%—11.42% | [27] |
 Kd | 15.88% | 12.71%—19.06% | [28] |
 PanVd | 31.15% | 24.92%—37.38% | [29] |
 Rd | 13.87% | 11.10%—16.65% | |
 ERd | 11.89% | 9.51%—14.27% | |
 KRd | 11.33% | 9.07%—13.60% | [30] |
 IxaRd | 9.80% | 7.84%—11.76% | [31] |
 DRd | 11.90% | 9.52%—14.28% | [6] |
 Kd | 19.28% | 15.42%—23.13% | |
 DKd | 25.26% | 20.21%—30.31% | |
 IsaKd | 13.28% | 10.62%—15.94% | |
Probability of background death | Chinese lifetable | Â | [35] |
Standard mortality rate | 3.94 | 3.15 – 4.73 | [36] |
Model starting age | |||
 Bortezomib group | 65 | 60 – 70 | |
 Lenalidomide group | 65 | 60 – 70 | |
 Carfilzomib group | 64 | 60—70 | |
Utility | |||
 Initial treatment during first 8 cycles | 0.67 | 0.54 – 0.80 | Collected by authors |
 Initial treatment after 8 cycles | 0.78 | 0.62 – 0.94 | Collected by authors |
 Subsequent treatment during first 8 cycles | 0.60 | 0.48 – 0.72 | Collected by authors |
 Subsequent treatment after 8 cycles | 0.72 | 0.58 – 0.86 | Collected by authors |
 Last treatment during first 8 cycles | 0.55 | 0.44 – 0.66 | Collected by authors |
 Last treatment after 8 cycles | 0.69 | – 0.83 | Collected by authors |